MVA Smallpox vaccine + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox
Conditions
Smallpox
Trial Timeline
Jul 1, 2005 → Jun 1, 2006
NCT ID
NCT00466245About MVA Smallpox vaccine + Placebo
MVA Smallpox vaccine + Placebo is a phase 2 stage product being developed by Sanofi for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT00466245. Target conditions include Smallpox.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00466245 | Phase 2 | Completed |
Competing Products
20 competing products in Smallpox
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Smallpox vaccine, LISTER strain, from chick embryo cells | Sanofi | Phase 2 | 51 |
| MVA (smallpox vaccine) | Sanofi | Phase 1 | 32 |
| ACAM3000 MVA Vaccine | Sanofi | Phase 1 | 32 |
| ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: Dryvax | Sanofi | Phase 2 | 51 |
| IMVAMUNE (MVA-BN) | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN | Bavarian Nordic | Phase 1 | 30 |
| IMVAMUNE® | Bavarian Nordic | Phase 2 | 49 |
| LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE® | Bavarian Nordic | Phase 2 | 49 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 49 |
| FD MVA-BN | Bavarian Nordic | Phase 3 | 74 |
| IMVAMUNE® | Bavarian Nordic | Phase 3 | 74 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN® (IMVAMUNE) + Placebo | Bavarian Nordic | Phase 2 | 49 |
| Elstree-BN | Bavarian Nordic | Phase 1 | 30 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 69 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| ACAM2000® smallpox vaccine | Emergent BioSolutions | Pre-clinical | 15 |
| Brincidofovir | Emergent BioSolutions | Phase 1 | 25 |
| Vaccination with ACAM2000 | Emergent BioSolutions | Approved | 77 |
| ACAM2000 Smallpox Vaccine + Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® | Emergent BioSolutions | Phase 2 | 44 |